<DOC>
	<DOCNO>NCT03006926</DOCNO>
	<brief_summary>This open-label Phase 1b study design evaluate tolerability safety lenvatinib combination pembrolizumab participant hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>A Trial Lenvatinib Plus Pembrolizumab Subjects With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Confirmed diagnosis hepatocellular carcinoma ( HCC ) HCC appropriate therapy available . Note : Expansion Part : No prior systemic therapy advanced/unresectable HCC Stage B ( applicable transarterial chemoembolization [ TACE ] ) , stage C base Barcelona Clinic Liver Cancer ( BCLC ) stag system At least 1 measurable target lesion accord modify Response Evaluation Criteria Solid Tumors ( mRECIST ) ChildPugh score A Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 Adequately control blood pressure Adequate renal function Adequate bone marrow function Adequate blood coagulation function Adequate liver function Males females age â‰¥ 18 year time inform consent Voluntary agreement provide write informed consent willingness ability comply aspects protocol Prior treatment lenvatinib antiPD1 , antiPDL1 , antiPDL2 agent Any current brain subdural metastasis Active malignancy ( except HCC definitively treat melanoma insitu , basal squamous cell carcinoma skin , carcinoma insitu cervix ) within past 36 month Any medical condition , opinion investigator , would preclude participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>E7080</keyword>
	<keyword>lenvatinib</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>Japan</keyword>
</DOC>